Fujifilm and Anicom Holdings's joint venture, Celltrust Animal Therapeutics Co., Ltd. started its operation in full swing, developing and providing cutting-edge veterinary technologies and services with focus on regenerative medicine

September 29, 2016
FUJIFILM Corporation
Anicom Holdings, Inc.

A joint venture company Celltrust Animal Therapeutics Co., Ltd. (President Yoshihiko Makino, hereafter Celltrust Animal Therapeutics) established by FUJIFILM Corporation (President Kenji Sukeno, hereafter Fujifilm) and Anicom Holdings, Inc. (President: Nobuteru Omori, hereafter Anicom) will start full scale operation from October 1. Celltrust Animal Therapeutics will develop and provide innovative and advanced medical technologies and services with the focus on regenerative medicine* in the field of cutting-edge veterinary medicine.

Celltrust Animal Therapeutics will aim to develop and commercialize innovative and advanced medical technologies and services with the focus on regenerative medicine in the field of cutting-edge veterinary medicine by combining Fujifilm's advanced production engineering and quality control technology nurtured in its photographic film business as well as regenerative medical technology, diagnostic imaging technology, and blood's chemical composition analysis technology , with Anicom's veterinary hospital network, electronic medical record system and extensive animal treatment data. In order to encourage the wider access to and adoption of the commercialized technologies and services, Celltrust Animal Therapeutics will provide new schemes for cutting-edge veterinary medicine by working together with veterinary clinics and incorporating Anicom Group's Pet Insurance. The developments of these advanced new social systems would also contribute to the application of regenerative medicine for humans.

<Celltrust Animal Therapeutics: Business overview>

- Development and practice of cutting-edge veterinary medicine

Celltrust Animal Therapeutics has established in Kanagawa Prefecture a center of translational research** where they develop advanced veterinary technologies and services, and also put them into medical practice. At the center, together with universities and companies, Celltrust Animal Therapeutics will develop therapeutic protocols including diagnostic methods and treatment grounded in cell therapy. Through the application of these advances, it will work to achieve commercialization of the new diagnosis and treatment methods. The center will include 1) facilities for cultivating the cells used in treatment with quality assurance system, 2) research facilities for carrying out science-based fundamental research and clinical development for cutting-edge treatments and 3) medical facilities for diagnosis.

- Provision of cutting-edge medical solutions

Celltrust Animal Therapeutics will provide cutting-edge medical solutions including the cutting-edge medical technologies and services developed at the center of translational research to primary veterinary clinics for diagnosis and treatment*** (hereafter primary treatment clinics). Furthermore, Celltrust Animal Therapeutics will also cooperate in the development of a new pet insurance scheme provided by the Anicom Group in order to reduce the burden of medical payments.

- Provision of medical information services

In order to provide cutting-edge medical services at primary treatment clinics, Celltrust Animal Therapeutics will provide a service to share diagnostic images taken at primary treatment clinics with external image specialists. The specialists can then return their diagnosis to the clinics. Furthermore, by storing and using evidence including therapeutic effects and medical imaging, Celltrust Animal Therapeutics will aim to develop more highly precise diagnosis and treatment methods.

[ Overview of Celltrust Animal Therapeutics Co., Ltd. ]

Company name Celltrust Animal Therapeutics Co., Ltd.
Address 9-7-3 Akasaka, Minato-ku, Tokyo, Japan
Date of foundation April 1, 2016
Capital 50 million yen (Shareholdings: Fujifilm:51% Anicom: 49%)
Business details Development and provision of advanced veterinary technologies and services
Executive Representative Director and President Yoshihiko Makino (from Fujifilm)
Director and Vice-President Tatsuhiko Kamei (from Anicom)
No. of employees 14
Website http://celltrust.jp/
  • * Regenerative medicine is a new field of medical technology for grafting artificially cultured cells and tissues to damaged organs and tissues to restore their functions.
  • ** Translational research refers to the re-evaluation of basic insight and technologies found in laboratories for their clinical application potential and their subsequent development to the stage of clinical use. In other words, it is a type of research that bridges between foundation studies and clinical studies.
  • *** Primary treatment refers to standard outpatient treatment and diagnosis. Primary treatment clinics receive a wide range of general patients. Secondary treatment hospitals provide specialist diagnosis and treatment.

For enquiries on information in this media release, contact:

Media Contact
FUJIFILM Corporation
Corporate Communications Division
TEL: +81-3-6271-2000
Anicom Holdings, Inc.
Corporate Planning Department
TEL: +81-3-5348-3911
Other Contact
FUJIFILM Corporation
Healthcare Business Development Office
TEL: +81-3-6271-2254
Anicom Holdings, Inc.
Corporate Planning Department
TEL: +81-3-5348-3911